Kouichi Tamura has received honoraria/lecture fee from AstraZeneca, Novartes, Bayer, Otsuka Pharmaceutical, Boehringer Ingelheim, Fuji Pharma, Kyowa Kirin, Ono Pharmaceutical, Sanwa Kagaku, Mochida Pharmaceutical, Kowa, Eli Lilly, Novo Nordisk, commissioned clinical trials, contract research and joint research funding: AstraZeneca, Bayer, Novartis, Chinook, Otsuka Medical Devices, Novo Nordisk, Terumo, Variatris, and Kowa, and, Scholarship donations: Otsuka Pharmaceutical, Bayer, Mochida Pharmaceutical, and Boehringer Ingelheim
Because whilst the potential pain benefits are interesting, there are specific reasons why the hypermobility and Ehlers-Danlos population needs to approach GLP-1 drugs with considerably more caution than the general public
This suggests that KBP-089 is responsible for the majority of the efficacy of the combination therapy in this study
GLP-1 receptor agonists are a class of medications primarily used to treat type 2 diabetes
EMERALD LABS B-HEALTHY 120 VEG